Business Wire

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Share

Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s scientists, creating a unique innovation ecosystem that is aimed at advancing scientific breakthroughs and enhancing research success.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204100180/en/

From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. (Photo: Business Wire)

The Hive builds on Almirall's open innovation centre, which began operations in 2023 with collaborations with two life science companies. The arrival of two new joiners announced today contribute to the creation of this unique collaboration ecosystem, following the initial partnerships with ZeClinics, a Contract Research Organization (CRO) specializing in genetics research using zebrafish as a model organism, and Centrient Pharmaceuticals, a global leader in sustainable biosynthetic pharmaceutical products.

The initiative was launched today as part of Almirall's 80th anniversary celebrations, bringing together health authorities, representatives from associations, entities, and institutions with whom Almirall closely collaborates to deliver against its commitment to patients, innovation, and the advancement of healthcare. The new joiners at The Hive include ADmit Therapeutics a company focused on the early detection of Alzheimer’s and other neurodegenerative diseases through technology that combines epigenetic and clinical data using machine learning. The most recent addition is Microomics a company specializing in metagenomic analysis using new DNA sequencing technologies (NGS).

"At Almirall, we bring together scientific experts from different disciplines in a collaborative environment as we see the transformative power collaboration has to push the boundaries of science and drive the development of novel solutions. An open innovation ecosystem that fosters this collaboration lays an exceptional foundation for breakthroughs in both scientific discovery and product development. We are proud to lead the way with The Hive, a unique initiative designed to advance science and innovation. By working together, we can address critical unmet needs and deliver meaningful progress in healthcare, ensuring that our innovations make a tangible difference in the lives of patients and their families", stated Dr. Karl Ziegelbauer, Almirall’s Chief Scientific Officer.

80 years of innovation and commitment to patients

Almirall is celebrating its 80th anniversary, marking eight decades of commitment to patients, innovation, and healthcare advancement. To commemorate this milestone, the company hosted an institutional event at its R&D centre in Barcelona, Spain. The event brought together health authorities, partners and institutional representatives, including the President of the Generalitat de Catalunya, Salvador Illa, Juan Cruz Cigudosa, Secretary of State for Science, Innovation, and Universities, María José Alonso, professor of Pharmacy and Pharmaceutical Technology at the University of Santiago de Compostela (USC), and Lourdes Borrell, Mayor of Sant Feliu de Llobregat.

Professor María José Alonso congratulated Almirall for its 80 decades “preserving the value of science and its transfer to industry in the best way, contributing to development and well-being, and elevating scientific value in the development of the Spanish innovative ecosystem, fostering a brighter future for all”.

Almirall was founded in Spain in 1944 with the purpose of giving people access to impactful medicines, a goal that continues to guide the company in its ambition as a leading medical dermatology. Almirall´s heritage, its deep scientific expertise, and the strong partnerships with the dermatology community worldwide are the foundation for its broad portfolio of dermatological treatments. Grounded in science and driven by innovation, the company continuously advances the understanding of skin diseases and provides solutions for even the most complex conditions. Based on this dedication, Almirall has become a leader in medical dermatology in Europe, with a strong portfolio of more than 50 products across different modalities, including topical, systemic, and biologics.

The company has invested 1 billion Euros in R&D in medical dermatology in the last decade which represents a continuous investment of over 12% of its annual net sales in R&D. This investment supports all phases of research conducted at its R&D centre – from discovery to late-stage clinical testing. Almirall’s close partnership with patients and dermatologists positions the company as a trusted and reliable partner, as it constantly focuses on understanding their needs to translate these into innovative solutions, helping improve people's lives both physically and emotionally.

Carlos Gallardo, Chairman and CEO of Almirall: "Celebrating 80 years is a testament to Almirall’s enduring commitment to innovation and patient care. Our journey has been driven by a profound dedication to improving patients' lives and providing meaningful treatments. As a family-owned company, we think in generations, and have consistently prioritized innovation in medical dermatology, investing over 1 billion Euros in R&D in this area over the last decade. We are grateful for the dedication of our teams across the company, and our partners and collaborators that enable us to help so many patients, every day. Our leading capabilities in skin biology and product development will continue to be a cornerstone of our mission, ensuring our sustained focus on science and innovation to deliver healthcare solutions to patients and the medical community."

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit https://www.almirall.com/

Legal notice:

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are "forward-looking statements." These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204100180/en/

Contacts

Corporate Communications:
corporate.communication@almirall.com
Phone: (+34) 659 614 173

Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AMP Raises $91 Million in Series D Funding to Revolutionize Waste5.12.2024 15:00:00 CET | Press Release

AMP Robotics Corp. (“AMP”), a leading provider of AI-powered sortation at scale for the waste and recycling industry, has raised $91 million in corporate equity in a Series D financing led by Congruent Ventures. The round featured participation from current and new investors, including Sequoia Capital, XN, Blue Earth Capital, Liberty Mutual Investments, California State Teachers Retirement System (CalSTRS), Wellington Management, Range Ventures, and Tao Capital Partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205769962/en/ AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems. AMP ONE provides a full-scale facility solution to sort various material streams and capture more of the billions of dollars in value otherwise lost to landfills or incinerated annually. (Photo: Business Wire) AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems, which are capabl

Andersen Global Inaugurates Member Firm in the Caribbean5.12.2024 15:00:00 CET | Press Release

Andersen Global continues to make an imprint on the global landscape as Robley Baynes, a collaborating firm since 2020, becomes a member firm and adopts the Andersen name. Andersen in Trinidad and Tobago is the first member firm in the Caribbean, debuting the Andersen brand in the region and further solidifying the organization’s global reach. Led by Partners Kendell Robley and Mikhail Baynes, Andersen in Trinidad and Tobago works closely with clients to deliver seamless service across tax, advisory, finance, corporate, and management. The firm’s client-focused business model ensures quality, integrated solutions are tailored to meet the growing global demands. “Our firm has developed tremendously over the years and our team diligently works to provide integrated, quality solutions in the evolving business landscape,” Kendell and Mikhail said. “By becoming a member firm of Andersen Global, we are committed to drive growth across the Caribbean and ensure client success.” Global Chairman

Vevo Therapeutics Partners with the Parse Biosciences GigaLab to Generate 100M Cell Atlas for AI Powered Drug Discovery5.12.2024 14:15:00 CET | Press Release

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the generation of the world’s largest single cell dataset to date, totaling 100 million cells. This impressive milestone was achieved in just one month using Parse Biosciences’ GigaLab and done in partnership with Vevo Therapeutics to advance their AI-based drug discovery efforts. The first-of-its-kind dataset, named Tahoe-100, comprises 100 million cells and 60,000 conditions with 1,200 drug treatments across 50 different tumor models. In addition to the AI drug discovery dataset generated with Vevo, the Parse GigaLab is currently working on large-scale projects for a variety of applications including additional perturbation screens, data for generative AI models, and atlasing for population studies. “This dataset is an important step forward for the Vevo team and the Mosaic platform,” said Johnny Yu, PhD, Chief Scientific Officer and Co-founder of Vevo. “Over the past 2

IonQ Unveils Its First Quantum Computer in Europe, Online Now at a Record #AQ365.12.2024 14:05:00 CET | Press Release

IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the delivery of IonQ Forte Enterprise to its first European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland. Achieved in partnership with QuantumBasel, this major milestone marks the first datacenter-ready quantum computer IonQ has delivered that will operate outside the United States and the first quantum system for commercial use in Switzerland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205805000/en/ IonQ European Innovation Center - Arlesheim, Switzerland (Photo: Business Wire) Forte Enterprise is now online servicing compute jobs while performing at a record algorithmic qubit count of #AQ36, which is significantly more powerful than the promised #AQ35. With each additional #AQ, the useful computational space for running quantum algorithms doubles. A system with #AQ36 is capable of considering more t

RSA Recognized in 2024 Gartner ® Magic Quadrant™ for Access Management5.12.2024 13:00:00 CET | Press Release

RSA, the security-first identity leader, announced today that RSA® ID Plus, the world’s most secure identity and access management (IAM) platform has been named a Niche Player in the 2024 Gartner® Magic Quadrant™ for Access Management. With only ten organizations named to the Gartner report, RSA believes that the Magic Quadrant signals the world’s top IAM vendors. ID Plus brings comprehensive identity protection to some of the world’s most security-sensitive organizations across banking, securities, insurance, and government. Available as SaaS, on-premises, or in hybrid configurations, ID Plus offers organizations flexibility in deployment and specialization in high-security workforce environments. Through various subscription models featuring a range of editions and add-ons, ID Plus meets diverse needs, supporting the evolving workforce requirements and regulatory landscapes throughout North America, South America, Europe, and the Asia-Pacific markets. RSA believes that several capabi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye